Skip to main content
SpringerLink
Log in

Malignant Neoplasm

  • Chapter
  • First Online:
The Yokohama System for Reporting Endometrial Cytology

Abstract

Endometrial endometrioid carcinoma is the most common histological type of endometrial carcinoma, accounting for more than 75% of all endometrial carcinomas. Histologically the tumor displays glandular, papillary with fine fibrovascular stroma, and solid pattern. Nuclear pseudostratification is usually observed and nuclear atypia is mild to moderate, and nucleoli are mostly nconspicuous. Cytologically almost all clusters show an irregular protrusion pattern, the nuclear overlap in epithelial cell clusters exceeds three layers, and the cohesion of stroma cells around the clusters is absent.

Histologically serous carcinoma shows papillary structures with delicate fibrovascluar stroma to thick fibrous stroma, and tumor cells are polygonal to columnar and show high-grade nuclear atypia, with a high N/C ratio. Cytologically shows nuclear overlapping of three or more layers and an irregular cellular arrangement in the clumps. Nuclei show swelling and marked pleomorphism with coarse nuclear chromatin and large and eosinophilic nucleoli.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bosse T, Lortet-Tieulent J, Davidson B, et al. Endometrioid carcinoma of the uterine corpus. In: WHO Classification of Tumor Editorial Board, editor. WHO classification of tumor of female reproductive organs. 5th ed. Lyon: IARC Press; 2020. p. 252–5.

    Google Scholar 

  2. Ellenson LH, Ronnett BM, Soslow RA, et al. Endometrial carcinoma. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein’s pathology of the female genital tract. 7th ed. New York: Springer-Verlag; 2019. p. 473–533.

    Chapter  Google Scholar 

  3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.

    Article  CAS  PubMed  Google Scholar 

  4. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15:e268–78.

    Article  PubMed  Google Scholar 

  5. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterisaion of endometrial carcinoma. Nature. 2013;497:57–73.

    Google Scholar 

  6. Norimatsu Y, Yanoh K, Kobayashi TK. The role of liquid-based preparation in the evaluation of endometrial cytology. Acta Cytol. 2013;57:423–35.

    Article  CAS  PubMed  Google Scholar 

  7. Yanoh K, Norimatsu Y, Munakata S, et al. Evaluation of endometrial cytology prepared with the Becton Dickinson SurePath™method:a pilot study by the Osaki study group. Acta Cytol. 2014;58:153–61.

    Article  PubMed  Google Scholar 

  8. Fulciniti F, Yanoh K, Karakitsos P, et al. The Yokohama system for reporting directly sampled endometrial cytology: the quest to develop a standardized terminology. Diagn Cytopathol. 2018;46:400–12.

    Article  PubMed  Google Scholar 

  9. Norimatsu Y, Kouda H, Kobayashi TK, et al. Utility of liquid-based cytology in endometrial pathology: diagnosis of endometrial carcinoma. Cytopathology. 2009;20:395–402.

    Article  CAS  PubMed  Google Scholar 

  10. Norimatsu Y, Yanoh K, Hirai Y, et al. A diagnostic approach to endometrial cytology by means of liquid-based preparations. Acta Cytol. 2020;64:195–207.

    Article  CAS  PubMed  Google Scholar 

  11. McAlpine J, Leon-Castillo A, Bosse T. The rise of novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018;244:538–49.

    Article  PubMed  Google Scholar 

  12. Sugiyama Y, Gotoh O, Fukui N, et al. Two distinct tumorigenic processes in endometrial endometrioid adenocarcinoma. Am J Pathol. 2020;190:234–51.

    Article  CAS  PubMed  Google Scholar 

  13. Zaino RJ, Kurman RJ, Diana KL, et al. The utility of the revised International Federation of Gynecology and Obstetrics histological grading of endometrial adenocarcinoma using a defined nuclear grading system. Cancer. 1995;75:81–6.

    Google Scholar 

  14. Norimatsu Y, Irino S, Maeda Y, et al. Nuclear morphometry as an adjunct to cytopathologic examination of endometrial brushings on LBC samples: a prospective approach to combined evaluation in endometrial neoplasms and look alikes. Cytopathology. 2021;32:65–74.

    Article  PubMed  Google Scholar 

  15. Hoang LN, Kinloch MA, Leo JM, et al. Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on the Cancer genome atlas (TCGA)-based molecular subgroup. Am J Sure Pathol. 2017;41:245–52.

    Article  Google Scholar 

  16. Hussein YR, Weigelt B, Levine DA, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28:505–14.

    Article  CAS  PubMed  Google Scholar 

  17. Conlon N, Da Cruz Paula ADC, Ashley CW, et al. Endometrial carcinomas with a “serous” component in young women are enriched for DNA mismatch repair deficiency, lynch syndrome, and POLE exonuclease domain mutations. Am J Surg Pathol. 2020;44:641–8.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Conlon N, Leitao MM Jr, Abu-Rustum NR, et al. Grading uterine endometrioid carcinoma. A proposal that binary is best. Am J Surg Pathol. 2014;38:1583–7.

    Article  PubMed  Google Scholar 

  19. Joehlin-Price A, Van Ziffle JV, Hills NK, et al. Molecularly classified uterine FIGO grade 3 endometrioid carcinomas show distinctive clinical outcomes but overlapping morphologic features. Am J Surg Pathol. 2021;45:421–9.

    Article  PubMed  Google Scholar 

  20. Bosse T, Nout RA, McAlpine JN, et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinctive prognostic subgroups. Am J Surg Pathol. 2018;42:561–8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Soslow RA, Tornos C, Park KJ, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol. 2019;38(Suppl 1):S64–S74.

    Google Scholar 

  22. Norimatsu Y, Miyamoto M, Kobayashi TK, et al. Diagnostic utility of phosphatase and tensin homolog, β-catenin, and p53 of endometrial carcinoma by thin-layer endometrial preparations. Cancer. 2008;114:155–64.

    Google Scholar 

  23. Di Lorito AD, Rosini S, Falo E, et al. Molecular alterations in endometrial archived liquid-based cytology. Diagn Cytopathol. 2013;41:492–6.

    Article  PubMed  Google Scholar 

  24. Di Lorito AD, Zappacosta R, Capanna S, et al. Expression of PTEN in endometrial liquid-based cytology. Acta Cytol. 2014;58:495–500.

    Google Scholar 

  25. Lu Li YW, Douville C, Cohen JD, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for detection of endometrial and ovaria cancers. Sci Transl Med. 2018;10:eaap8793. https://doi.org/10.1126/scitranslemd.aap8793.

    Article  PubMed  Google Scholar 

  26. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.

    Article  CAS  PubMed  Google Scholar 

  27. Hendrickson M, Ross J. Eifel, et al. Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108.

    Article  CAS  PubMed  Google Scholar 

  28. Sherman ME, Rosenshein NB, Kurman RJ, et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathological features. Am J Surg Pathol. 1992;16:600–10.

    Article  CAS  PubMed  Google Scholar 

  29. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198:218.e1–6.

    Google Scholar 

  30. Moll UM, Chalas E, Auguste M, et al. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol. 1996;27:1295–300.

    Article  CAS  PubMed  Google Scholar 

  31. Tashiro H, Isacson C, Levine R, et al. p53 gene mutation in uterine serous carcinoma and occurs early in their pathogenesis. Am J Pathol. 1997;150:177–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterizaion of endometrial carcinoma. Nature. 2013;497:57–73.

    Google Scholar 

  33. Ellenson LH, Parkash V, Stewart CJR. Serous carcinoma of the uterine corpus. In: WHO Classification of Tumor Editorial Board, editor. WHO classification of tumor of female reproductive organs. 5th ed. Lyon: IARC Press; 2020. p. 256–7.

    Google Scholar 

  34. Ellenson LH, Ronnett BM, Soslow RA, et al. Endometrial carcinoma. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein’s pathology of the female genital tract. 7th ed. New York: Springer-Verlag; 2019. p. 473–533.

    Chapter  Google Scholar 

  35. Zaino R, Carinelli SG, Ellenson LH, et al. Epithelial tumours and precursors. In: Kurman RJ, Carangiu ML, Herrington CS, et al., editors. WHO classification of tumor of female reproductive organs. 4th ed. Lyon: IARC Press; 2014. p. 125–35.

    Google Scholar 

  36. Carcangiu ML, Tan LK, Chambers JT. Stage IA uterine serous carcinoma: A study of 13 cases. Am J Surg Pathol. 1997;21:1507–14.

    Article  CAS  PubMed  Google Scholar 

  37. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma. Diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797–806.

    Article  CAS  PubMed  Google Scholar 

  38. Hui P, Kelly M, O’Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathologic study of 40 cases. Mod Pathol. 2005;18:75–82.

    Article  PubMed  Google Scholar 

  39. Zheng W, Xiang L, Fadare O, et al. A proposed model of endometrial serous carcinogenisis. Am J Surg Pathol. 2011;35:e1–e14.

    Article  PubMed  Google Scholar 

  40. Yasuda M, Katoh T, Hori S, et al. Endometrial intraepithelial carcinoma in association with polyp: review of eight cases. Diagn Pathol. 2013;8:25–31.

    Google Scholar 

  41. Umezawa T, Nomura K, Tsuchiya S, et al. Serous endometrial intraepithelial carcinoma. J Jpn Soc Clin Cytol. 2012;51:188–91. (in Japanese with English abstract).

    Google Scholar 

  42. Zheng W, Yi X, Fadare O, et al. The Oncofetal protein, IMP3. a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304–15.

    Google Scholar 

  43. Yomelyanova A, Ji H, Shih IM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas. Immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504–14.

    Article  Google Scholar 

  44. Fadare O, Zheng W. Endometrial glandular dysplasia (EmGD):morphological and biologically distinctive putative precursor lesion of Type II endometrial cancers. Diagn Pathol. 2008;3:6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Jarboe EA, Miron A, Monte N, et al. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol. 2009;22:345–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Silverberg SG, De Giorgi LS. Clear cell carcinoma of the endometrium. Clinical, pathologic, and ultrastructural findings. Cancer. 1973;31:1127–40.

    Google Scholar 

  47. Ellenson LH, Ronnett BM, Soslow RA, et al. Endometrial carcinoma. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein’s pathology of the female genital tract. 7th ed. New York: Springer-Verlag; 2019. p. 473–533.

    Chapter  Google Scholar 

  48. Abeler VM, Vergote IB, Kjorstad KE, et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996;78:1740–7.

    Article  CAS  PubMed  Google Scholar 

  49. Fadare O, Stewart CJR. Clear cell carcinoma of the uterine corpus. In: WHO Classification of Tumor Editorial Board, editor. WHO classification of tumor of female reproductive organs. 5th ed. Lyon: IARC Press; 2020. p. 258–9.

    Google Scholar 

  50. DeLair DF, Burke KA, Selenica P, et al. The genetic landscape of endometrial clear cell carcinomas. J Pathol. 2017;243:230–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Ellenson LH, Ronnett BM, Soslow RA, et al. Endometrial carcinoma. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein’s pathology of the female genital tract. 7th ed. New York: Springer-Verlag; 2019. p. 473–533.

    Chapter  Google Scholar 

  52. Wakui K, Matsui N, Yasuda M, et al. Cytological study of endometrial clear cell carcinoma. Analysis of structural pattern of tumor cells. J Jpn Clin Cytol. 2008;47:269–74. (in Japanese with English abstract).

    Google Scholar 

  53. Fadare O, Desouki MM, Gwin K, et al. Frequent expression of Napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38:189–96.

    Google Scholar 

  54. Lim D, Philip PC, Cheung ANY, et al. Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma. Am J Surg Pathol. 2015;39:1061–9.

    Article  PubMed  Google Scholar 

  55. Ip PPC, Djordjevic B. Arias-Stella reaction of the uterine corpus. In: WHO Classification of Tumours Editorial Board, editor. WHO Classification of tumor of female reproductive organs. 5th ed. Lyon: IARC Press; 2020. p. 271.

    Google Scholar 

  56. Philip PC, Wang SY, Wong OGW, et al. Napsin A, Hepatocyte Nuclear Factor −1-Beta (HNF-1β), Estrogen and Progesteron receptors expression in Arias-Stella raction. Am J Surg Pathol. 2019;43:325–33.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Pathology, Toyama Red Cross Hospital, Toyama, Japan

    Yoshinobu Maeda

  2. Department of Diagnostic Cytopathology, Kurume University Hospital, Fukuoka, Japan

    Akihiko Kawahara

  3. Department of Diagnostic Pathology, Nara Medical University Hospital, Kashihara, Nara, Japan

    Takeshi Nishikawa

  4. Department of Medical Technology, Faculty of Health Sciences, Ehime Prefectural University of Health Sciences, Tobe-cho, Iyo-gun, Ehime, Japan

    Yoshiaki Norimatsu

Authors
  1. Yoshinobu Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akihiko Kawahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshiaki Norimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiaki Norimatsu .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Medicine, Dokkyo Medical University, Tochigi, Japan

    Yasuo Hirai

  2. Clinical Cytology Service, Istituto Cantonale dì Patologia, Ente Ospedaliero Cantonale, Locarno, Switzerland

    Franco Fulciniti

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Maeda, Y., Kawahara, A., Nishikawa, T., Norimatsu, Y. (2022). Malignant Neoplasm. In: Hirai, Y., Fulciniti, F. (eds) The Yokohama System for Reporting Endometrial Cytology. Springer, Singapore. https://doi.org/10.1007/978-981-16-5011-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-5011-6_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-5010-9

  • Online ISBN: 978-981-16-5011-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation